TX-ASCEND-PERFORMANCE
15.6.2020 21:13:10 CEST | Business Wire | Press release
Ascend Performance Materials has introduced Acteev Protect™, a breakthrough technology specially formulated to guard against the growth of mildew, fungi and other microbes to keep textiles and nonwoven fabrics fresher for longer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005732/en/
The technology is a leap forward in protection for face masks, apparel, upholstery, air filters and more, said Lu Zhang, Ph.D., Ascend’s vice president leading the Acteev launch. “Bacteria, mildew and other microbes growing on fabrics and filters cause the item to break down, discolor and give off unpleasant smells,” she said. “Acteev Protect guards against that microbial growth, keeping the articles clean.”
The technology has been in development for several years, but with the recent shortage of articles resistant to microbial growth, Ascend accelerated the product launch by partnering with independent labs for testing and reallocating resources to scale up production. “The current global scarcity of microbe-resistant materials is not going to end unless manufacturers are able to obtain the right media,” Dr. Zhang said. “We saw a way we could quickly meet those urgent needs with this innovative technology.”
Acteev Protect combines zinc ion technology with polyamide-based woven, nonwoven and knit fabrics. The active zinc ions are embedded into the polymer matrix, providing a long-lasting solution that does not wash away, unlike topical finishes or coatings. The polyamide fabrics are durable yet soft to the skin, and the nonwoven filtration media – available as nanofibers, meltblown and spunbond – efficiently keep out unwanted particles.
The embedded zinc in its ionic form is a powerful inhibitor of bacterial growth, said Vikram Gopal, Ph.D., Ascend’s senior vice president of technology. “Zinc is an essential element needed for bacterial growth, so bacteria readily allows it inside the cell body. But the zinc ion outcompetes other essential elements such as manganese and magnesium and chokes their ingestion channels,” he said. “Without those minerals, the microbes can’t grow or reproduce.”
Other products use silver as an antimicrobial, Dr. Gopal said, but that metal comes with unwanted environmental consequences. “Silver is typically used as a finish or a coating,” he said. “That process is water-intensive, and the excess silver has to be disposed of, eventually ending up in our waterways.”
Zinc, however, is labeled Generally Regarded as Safe by the U.S. Food and Drug Administration.
Additionally, the fabrics feature all the benefits of premium polyamides, which offer more comfort than polypropylene in single-use masks and allows knits and wovens to be dyed, printed on and laundered.
Polyamide 66 wovens and knits have considerable advantages over other types of nylons in garments and other textile applications, said Harrie Schoots, president-elect of the American Association of Textile Chemists and Colorists and a senior business leader of Ascend’s textile business.
“This material resists abrasion and doesn’t pill or shed microfibers. It has a soft hand and excellent drape, and it can be dyed solid or bright colors,” Schoots said. “Uniforms or activewear made with Acteev Protect will be durable and comfortable and can be designed to match current color trends.”
Additionally, these features will last the lifetime of the garment. “Because the zinc ions are embedded during the polymerization process, knit and woven articles made with Acteev Protect stand up to 50 washes or more,” Schoots said.
Ascend is the world’s largest fully integrated producer of polyamide 66 resins and also manufactures fibers and chemicals. Acteev Protect is the company’s first product offering available in ready-to-use fabric form factors. The company plans to extend the line in the coming months to include polyamide 66 fabrics for medical applications and engineered plastics for high-touch surfaces.
For more information, to request a sample or to see performance data, please visit ascendmaterials.com/acteevprotect .
Acteev Protect does not protect users or others against disease-causing bacteria.
About Ascend Performance Materials
Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has nine global locations, including five fully-integrated manufacturing facilities located in the southeastern United States and an engineering plastics compounding facility in Europe, all dedicated to the innovation and safe production. With three of the world’s largest chemical processing facilities, Ascend’s materials form the building blocks for products used in everyday applications from apparel to airbags, cable ties to circuit boards and carpets to car parts. Ascend’s 2,600-person global workforce is committed to making a difference in the communities we serve and leading the development of material solutions that inspire everyone, everywhere, every day.
Together, we’re making a difference.
Together, we’re inspiring everyday.
More information about Ascend can be found at www.ascendmaterials.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005732/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom